[PDF][PDF] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga, J Albanell, A Ruiz, A Lluch, P Gascón… - J Clin Oncol, 2005 - academia.edu
J Baselga, J Albanell, A Ruiz, A Lluch, P Gascón, V Guillém, S González, S Sauleda…
J Clin Oncol, 2005•academia.eduPhase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast
Cancer Page 1 Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with
Advanced Breast Cancer José Baselga, Joan Albanell, Amparo Ruiz, Ana Lluch, Pere Gascón,
Vicente Guillém, Sonia González, Silvia Sauleda, Irene Marimón, Josep M. Tabernero, Maria T.
Koehler, and Federico Rojo From the Vall d’Hebron University Hospital; Hospital Clinic,
Barcelona; Instituto Valenciano de Oncologia; Universitat de Valencia, Hospital Clınico …
Cancer Page 1 Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with
Advanced Breast Cancer José Baselga, Joan Albanell, Amparo Ruiz, Ana Lluch, Pere Gascón,
Vicente Guillém, Sonia González, Silvia Sauleda, Irene Marimón, Josep M. Tabernero, Maria T.
Koehler, and Federico Rojo From the Vall d’Hebron University Hospital; Hospital Clinic,
Barcelona; Instituto Valenciano de Oncologia; Universitat de Valencia, Hospital Clınico …
Purpose
To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer.
academia.edu